Bavarian Nordic's COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster push

Bavarian Nordic has evidence its COVID-19 vaccine may hold up against omicron. With a midphase trial finding antibody titers were boosted to levels associated with a high level of protection, the biopharma is pushing ahead with plans to move into a phase 3 study.